Companies · Biotechnology

In-Pipe Technology Company, Inc.

Wheaton · Biotechnology

Diligence memoA one-page analyst read on In-Pipe Technology Company, Inc. — recommendation, valuation, rhythm, risks.
$7.0M
Total raised · real
2
Rounds
0.4×
Latest step-up
Top 51%
Sector rank · raised
Series A
Latest stage · inferred · Mon Aug 09 2010 00:00:00 GMT+0000 (Coordinated Universal Time)

In-Pipe Technology Company, Inc. looks under-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.36× the median modeled value of Series A Biotechnology companies in 2010–2012 (92 peers) — value vs value, same stage and era.
Dormant
  • Last raise 15.9 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

In-Pipe Technology Company, Inc. is one of 4291 Biotechnology companies tracked from Wheaton. By capital raised it ranks mid-pack (ahead of 50% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$50M$100M$150M$200MSeries A · 2009-08-06 Raised $5.0M (real) Modeled valuation $181M (est)$5.0M$181MSeries A2009Series A · 2010-08-09 Raised $2.0M (real) Modeled valuation $72M (est)$2.0M$72MSeries A2010+$2.0MCumulative $7.0M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series A$5.0M · 2009
Series A extension$2.0M · 2010

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 33%.

Modeled valuation trajectory
$72.3M
Base estimate est.
$2.2M
Conservative case
$393.1M
Upside case
$9.1M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Aa $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Series A · modeled $180.8M · 2009-08-062009Series A · modeled $72.3M · 2010-08-092010
Model inputs · modeled:benchmark-stage-stepup-v1
22%
Dilution assumption
Implied ownership sold in the financing.
44%
Survival probability
24% low · 60% high
1.62×/yr
Annual markup
2.04×/yr upside case
6.0 yr
Elapsed time used
15.9 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
12 mo
Avg between rounds
$6.9M/yr
Capital velocity
16.9 yr
On record since
2009
First round
2
Rounds on file
How it compares to the market

Benchmarked against 4291 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 1.0× of median
This company$7.0M
Sector median$7.2M
Latest round — vs other Series A rounds in sector (real $, this stage) 0.4× of median
This company$2.0M
Sector median$5.4M
Modeled value — vs sector median (estimate, all stages) 1.1× above median
This company$72.3M
Sector median$64.2M

Raised more than 50% of sector peers (real $). Modeled value above 53% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #78 of 92.

This companyCohort peer
$10.0M$100.0M$1.0B$1.0M$10.0M$100.0MCapital raised (log)Tobira Therapeutics, Inc. · Series A Raised $23.2M · modeled $513.3M (est)Neoprobe Corp · Series A Raised $14.0M · modeled $506.1M (est)Akebia Therapeutics, Inc. · Series A Raised $25.9M · modeled $504.1M (est)Adimab, LLC · Series A Raised $13.8M · modeled $499.5M (est)Elevation Pharmaceuticals Inc · Series A Raised $27.4M · modeled $448.3M (est)Mnemosyne Pharmaceuticals Inc · Series A Raised $24.0M · modeled $445.8M (est)Macrogenics Inc · Series A Raised $12.0M · modeled $434.4M (est)Neurologica Corp · Series A Raised $17.0M · modeled $433.8M (est)Bodymedia Inc · Series A Raised $20.1M · modeled $429.9M (est)Peloton Therapeutics, Inc. · Series A Raised $13.7M · modeled $423.0M (est)Seahorse Bioscience Inc · Series A Raised $20.7M · modeled $410.2M (est)Stemgent, Inc. · Series A Raised $37.9M · modeled $408.5M (est)In-Pipe Technology Company, Inc. (this company) Raised $7.0M · modeled $72.3M (est)In-Pipe Technology Company, Inc.
CompanyStageRaised · realValue · estvs peer med.
Tobira Therapeutics, Inc.Series A$23.2M$513.3M2.56×
Neoprobe CorpSeries A$14.0M$506.1M2.53×
Akebia Therapeutics, Inc.Series A$25.9M$504.1M2.52×
Adimab, LLCSeries A$13.8M$499.5M2.50×
Elevation Pharmaceuticals IncSeries A$27.4M$448.3M2.24×
Mnemosyne Pharmaceuticals IncSeries A$24.0M$445.8M2.23×
Macrogenics IncSeries A$12.0M$434.4M2.17×
Neurologica CorpSeries A$17.0M$433.8M2.17×
Bodymedia IncSeries A$20.1M$429.9M2.15×
Peloton Therapeutics, Inc.Series A$13.7M$423.0M2.11×
Seahorse Bioscience IncSeries A$20.7M$410.2M2.05×
Stemgent, Inc.Series A$37.9M$408.5M2.04×
In-Pipe Technology Company, Inc. this companySeries A$7.0M$72.3M0.36×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series A$5.0M2009-08-06$22.7M$180.8M90%
Series A$2.0M2010-08-09$9.1M$72.3M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series A$5.0M2009-08-06
    • First recorded raise — entered as Series A.
  2. Series A$2.0M2010-08-09
    • Raised 12 mo later, in step with the ~14 mo sector norm.
    • Round 2.5× smaller than the prior — bridge or down round.
Intelligence
2011 ~Q3
Modeled next raise · ~12mo cadence
$2.0M
Modeled next size est.range $2.0M$3.2M
0.4×
Last step-up
$6.9M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Donald Sackman3 other2009-08
Valerie Daoud Henderson1 other2009-08
Daniel R. Williamson, Jr.2009-08
Donald Daoud Sackman2010-08
Fadi Kassir2009-08
Francis John Williams2009-08
Jason Daoud Macatangay2010-08
J Rodney Dickerson2009-08
Susan Daoud Lally2010-08
Susan Lally2009-08
William John Mondi2010-08
William Mondi2009-08
Registry & provenance

In-Pipe Technology Company, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1412526
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Synoligo Biotechnologies, Inc.BiotechnologySeries A$7.0M$89.1Msame sector · same stage
Ribonaut Therapeutics, Inc.BiotechnologySeries A$6.9M$79.6Msame sector · same stage
Inspired Technologies IncBiotechnologySeries A$7.1M$56.9Msame sector · same stage
Secretome Therapeutics, Inc.BiotechnologySeries A$6.9M$78.0Msame sector · same stage
Shennon Biotechnologies Inc.BiotechnologySeries A$7.3M$80.0Msame sector · same stage
Sendero Biotechnology, Inc.BiotechnologySeries A$7.3M$69.1Msame sector · same stage
TC BioPharm (Holdings) plcBiotechnologySeries A$7.3M$82.8Msame sector · same stage
Cytosolix, Inc.BiotechnologySeries A$6.6M$57.6Msame sector · same stage
Frequently asked
How much funding has In-Pipe Technology Company, Inc. raised?
In-Pipe Technology Company, Inc. has raised approximately $7.0M in disclosed capital across 2 recorded financing rounds, aggregated from public filings.
What is In-Pipe Technology Company, Inc.'s estimated valuation?
Provath's modeled valuation for In-Pipe Technology Company, Inc. is approximately $72.3M (modeled range $2.2M–$393.1M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is In-Pipe Technology Company, Inc. at?
In-Pipe Technology Company, Inc.'s latest modeled financing stage is Series A. Its most recent recorded round closed around Mon Aug 09.
What does In-Pipe Technology Company, Inc. do and where is it based?
In-Pipe Technology Company, Inc. operates in the Biotechnology sector, based in Wheaton.
Explore related

See where In-Pipe Technology Company, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at In-Pipe Technology Company, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.